
Monday, September 16, 2024 7:29:23 AM
Not as good as i was thinking yesterday, also looks like BMS is pulling out.
https://finance.yahoo.com/news/immatics-presents-clinical-proof-concept-092500575.html
Remember this was targetting mage, IMA402 was targetting prame, so there is still hope those results are better. Hope we get an update on IMA402 before year end. TCRX has had excellent success with leukemia targetting prame.
I have to admit today's news is not that good, imo
Recent IMTX News
- Immatics IMA203 PRAME Cell Therapy Data Presented at 2025 ASCO Annual Meeting Continues to Show Strong Anti-tumor Activity and Durability in Patients with Metastatic Melanoma • GlobeNewswire Inc. • 05/31/2025 12:00:00 PM
- Immatics Announces First Quarter 2025 Financial Results and Business Update • GlobeNewswire Inc. • 05/13/2025 11:00:00 AM
- Immatics Announces Upcoming Oral and Poster Presentation on IMA203 TCR T-cell Therapy at 2025 ASCO Annual Meeting • GlobeNewswire Inc. • 04/23/2025 02:00:00 PM
- Immatics Announces Full Year 2024 Financial Results and Business Update • GlobeNewswire Inc. • 03/27/2025 11:00:00 AM
- Immatics Announces Third Quarter 2024 Financial Results, Business Update and First Clinical Data on TCER® IMA402 Targeting PRAME • GlobeNewswire Inc. • 11/18/2024 12:00:00 PM
- Immatics Announces Multiple Presentations at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) on TCR-T Therapy Candidates Targeting PRAME • GlobeNewswire Inc. • 11/08/2024 10:00:00 PM
- Immatics Announces Pricing of $150 Million Public Offering • GlobeNewswire Inc. • 10/11/2024 12:50:00 AM
- Immatics Announces Proposed $150 Million Public Offering • GlobeNewswire Inc. • 10/10/2024 11:30:00 AM
- Immatics Announces Updated Phase 1b Clinical Data on ACTengine® IMA203 TCR-T Targeting PRAME in Melanoma Patients and Provides Update on Upcoming SUPRAME Phase 3 Trial • GlobeNewswire Inc. • 10/10/2024 10:30:00 AM
- Immatics Announces Upcoming Oral and Poster Presentations at the Society for Immunotherapy of Cancer Annual Meeting 2024 • GlobeNewswire Inc. • 10/04/2024 01:00:00 PM
- Immatics Presents Clinical Proof-of-Concept Data from Ongoing Phase 1 Dose Escalation Trial with TCR Bispecific Molecule TCER® IMA401 Targeting MAGEA4/8 at ESMO 2024 and Provides Development Update • GlobeNewswire Inc. • 09/16/2024 09:25:00 AM
- Immatics Announces Upcoming Oral Presentation at the Society for Melanoma Research Congress 2024 • GlobeNewswire Inc. • 09/06/2024 11:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 08/13/2024 11:07:01 AM
- Immatics Announces Second Quarter 2024 Financial Results and Business Update • GlobeNewswire Inc. • 08/13/2024 11:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 07/31/2024 11:07:40 AM
- Immatics Appoints Alise Reicin to Board of Directors • GlobeNewswire Inc. • 07/31/2024 11:00:00 AM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 07/22/2024 08:05:27 PM
- Immatics Announces Upcoming Oral Presentation at ESMO Congress 2024 • GlobeNewswire Inc. • 07/18/2024 01:00:00 PM
VAYK to Acquire Up to $9 million in Time-share Vacation Properties Through Non-Cash Deals • VAYK • Jun 11, 2025 9:45 AM
ECGI Holdings Invests in AI-Powered Fantasy Sports Startup Payday Fantasy • ECGI • Jun 10, 2025 8:30 AM
Avant Technologies Signs Letter of Intent for a Business Combination • AVAI • Jun 10, 2025 8:00 AM
NEXT10, Inc. Announces Acquisition of Torreon Group, Inc. • NXTN • Jun 9, 2025 8:42 AM
Maybacks Global Entertainment, LLC and Plex Sign Global Licensing and Distribution Agreement • AHRO • Jun 6, 2025 8:30 AM
Omega Laboratories Delivers Marijuana Breath Test Validation Packet to Cannabix Technologies Inc. - Completing Major Milestone under Strategic Partnership • BLOZF • Jun 5, 2025 8:54 AM